Document Detail


Hearing changes after diagnosis in neurofibromatosis type 2.
MedLine Citation:
PMID:  15021775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Describe the changes in hearing ability and progression of disease over time in subjects with neurofibromatosis Type 2 enrolled in a multicenter natural history study of vestibular schwannomas in neurofibromatosis Type 2. STUDY DESIGN: Retrospective clinical study. SETTING: International neurofibromatosis Type 2 tertiary care centers. PATIENTS: Study participants had a clinical diagnosis of neurofibromatosis Type 2, at least one untreated vestibular schwannoma, and were at least 5 years old. Sixty-three subjects (108 ears) with audiology data at either short-term follow-up (7 mo-2 yr) or long-term follow-up (3-5 yr) after diagnosis were examined in this study. MAIN OUTCOME MEASURES: Changes in four-frequency pure-tone average and speech discrimination score before any treatment intervention for both follow-up intervals. RESULTS: Within 2 years of the diagnosis of neurofibromatosis Type 2, 27% of the ears experienced a significant loss in pure-tone average relative to diagnosis, and 73% of the ears experienced no significant change in hearing. CONCLUSION: Newly diagnosed neurofibromatosis Type 2 patients who do not require immediate treatment of both vestibular schwannomas are likely to have stable hearing in the unoperated ear(s) for approximately 1 to 2 years.
Authors:
Ann Masuda; Laurel M Fisher; Mark L Oppenheimer; Zarina Iqbal; William H Slattery;
Related Documents :
23744795 - Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome acc...
24400915 - A comparison of ketamine and morphine analgesia in prehospital trauma care: a cluster r...
24975005 - Orthodontic traction in a patient with cleidocranial dysplasia: 3 years of follow-up.
23974915 - Patient-reported visual function outcomes improve after ranibizumab treatment in patien...
16109135 - Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
20533545 - The efficacy and safety of abatacept in patients with non-life-threatening manifestatio...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology     Volume:  25     ISSN:  1531-7129     ISO Abbreviation:  Otol. Neurotol.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-03-15     Completed Date:  2004-07-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100961504     Medline TA:  Otol Neurotol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  150-4     Citation Subset:  IM    
Affiliation:
Clinical Studies Department, House Ear Institute, Los Angeles, California 90057, USA. amasuda@hei.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Audiometry, Pure-Tone / methods
Auditory Threshold*
Child
Child, Preschool
Disease Progression
Female
Follow-Up Studies
Hearing Loss / diagnosis,  etiology*
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neurofibromatosis 2 / complications,  physiopathology*
Neuroma, Acoustic / complications,  physiopathology*
Regression Analysis
Retrospective Studies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical usefulness of extratympanic electrocochleography in the diagnosis of Ménière's disease.
Next Document:  Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocr...